Spots Global Cancer Trial Database for Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.
Official Title: Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.
Study ID: NCT04368273
Conditions
Interventions
Study Description
Brief Summary: To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin concurrent IMRT for locally advanced cervical cancer.
Detailed Description: The dose of toripalimab injection (pd-1 antibody) was 240mg/d, d1, i.v. every 14d, totally 4 cycles (56 days) Concurrent chemoradiotherapy: Cisplatin 40 mg/m2 i.v., d1, administered once a week; Radiotherapy: pelvic intensity modulated radiotherapy, prescription dose DT: 50.4gy /2Gy/28f;After intraluminal irradiation DT: 30-36 Gy/6Gy/5-6f 2f/w, complete the radiotherapy within 56 days. Complete at least 4 cycles of concurrent chemoradiotherapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Peking University 3rd Hospital, Beijing, Beijng, China
Contact Details
Name: Junjie Wang, MD
Affiliation: Peking University 3rd Hospital radiation oncology department
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
